Hims & Hers shares climbed over 20% in June, breaching $30 ahead of the July 23–24 FDA meeting on adding seven peptides to the 503A Bulk List. Analysts predict peptide approval could yield $10–19 billion revenue by 2030 and support growth beyond 2027, while near-term focus stays on GLP-1 post-Eucalyptus acquisition.
Shares of Hims & Hers climbed over 20% in June, breaching the $30 level that had served as resistance in April. This rally reflects heightened investor optimism ahead of the FDA’s peptide review process.
The Pharmacy Compounding Advisory Committee will convene July 23–24 to deliberate adding seven peptides to the FDA’s 503A Bulk List, enabling pharmacy compounders to produce these therapies. A positive vote could accelerate product launch timelines, though final FDA approval remains pending.
Analysts predict approval of compounded peptides could drive $10–19 billion in annual peptide revenue by 2030 and underpin growth beyond 2027. Leerink has retained a Market Perform rating with a $25 price target, highlighting high uncertainty but significant upside potential.
Despite long-term peptide opportunities, near-term attention remains on GLP-1 treatments following the Eucalyptus acquisition and Juniper platform’s UK pre-orders for Novo Nordisk’s oral Wegovy. Continued GLP-1 performance will be critical for sustaining profitability trends.
